New Synthesized Derivatives from N-Substituted-4-Oxo- Benzopyrano [4,3-c] Pyrazole Influenced Proliferation, Viability, Spreading and Invasion of Human Liver Tumor Cells
AbstractBackground/Aim: There is an unsatisfied clinical demand to develop new anticancer agents. The aim of the current study was to synthesize new coumarin derivatives using two different synthetic methodologies and to evaluate their anticancer activity. Materials and methods: Four coumarin derivatives were synthesized and evaluated for their anticancer activities. The structures of all compounds were confirmed by infrared (IR), UV-vis, Nuclear magnetic resonance (NMR) 13C NMR, 1H NMR, and high-resolution mass spectrometry (HRMS) analysis. All the synthesized compounds (4, 5, 8 and 9) were analyzed for their anti-proliferative (MTT and LDH assays and cell cycle studied with flow cytometry) and anti-invasive activity (spreading and invasion tests) on human hepatoma cell lines Huh-7 in vitro. Doxorubicin was used as control in order to compare their anti-tumoral effects. Results. All the synthesized compounds are potential inhibitors of proliferation, viability, spreading and invasion of human liver tumor cells with a 50% inhibitory Concentration range, IC50=10.37 μM to 12.94 μM. Conclusion. This study could lead to the identification of a new target therapy for human Hepatocellular carcinoma (HCC) or other cancers.
World Health Organization: World Cancer Report. pp. Chapter 5.6: ISBN 9283204298, 2014.
Poole SK, Poole CF. “Thin-layer chromatographic method for the determination of the principal polar aromatic flavour compounds of the cinnamons of commerce”. Analyst, 119;113-120, 1994.
Rosselli S, Maggio AM, Faraone N, Spadaro V, Morris-Natschke SL, KF Bastow, Lee KH, Bruno M.”The cytotoxic properties of natural coumarins isolated from roots of Ferulagocampestris (Apiaceae) and of synthetic ester derivatives of aegelinol”. Nat Prod Commun, 4;1701-1706, 2009.
Whang WK, Park HS, Ham I, Oh M, Namkoong H, Kim KH, Hwang DW, Hur SY, Kim TE, Park YG. “Natural compounds, fraxin and chemicals structurally related to fraxin protect cells from oxidative stress”. Exp Mol Med ,37; 436-446, 2005.
Shin E, Choi KM, Yoo HS, Lee CK, Hwang BY, Lee MK.” Inhibitory effects of coumarins from the stem barks of Fraxinusrhynchophylla on adipocyte differentiation in 3T3-L1 cells”. Biol Pharm Bull ,33; 1610-1614, 2010.
Teng CM, Lin CH, Ko FN, Wu TS, Huang TF.” The relaxant action of osthole isolated from Angelica pubescens in guinea-pig trachea, Schmiedeb”. Arch Pharmacol ,349; 202-208, 1994.
Crichton EG, Waterman PG, Dihydromammea c/ob.” a new coumarin from the seed of Mammea Africana”. Phytochemistry ,17;1783-1786, 1978.
Baek NI, Ahn AM, Kim HY, Park YD.” Furanocoumarins from the root of Angelica dahurica”. Arch Pharm Res, 23;467-470, 2000.
Fort D, Rao K, Jolad S, Luo J, Carlson J, King S.” Antihyperglycemic activity of Teramnuslabialis (Fabaceae)”. Phytomedicine ,6;465-467, 2000.
Piller N.” A comparison of the effectiveness of some anti-inflammatory drugs on thermal oedema”, Br J Exp Pathol , 56; 554, 1975.
Patil AD, Freyer AJ, Eggleston DS, Haltiwanger RC, Bean MF, Taylor PB, Caranfa MJ, Breen AL, Bartus HR.” The inophyllums, novel inhibitors of HIV-1 reverse transcriptase isolated from the Malaysian tree, Calophylluminophyllum Linn”. J Med Chem ,36; 4131-4138, 1993.
Spino, Dodier M, Sotheeswaran S.” Anti-HIV coumarins from Calophyllum seed oil, Bioorg”. Med Chem Lett ,8; 3475-3478, 1998.
Luo KW, Sun JG, Chan JW, Yang L, Wu SH, Fung KP, Liu FY.” Anticancer effects of imperatorin isolated from Angelica dahurica: induction of apoptosis in HepG2 cells through both death-receptor-and mitochondria mediated pathways”. Chemotherapy ,57; 449-459, 2011.
Velasco-Velázquez MA, Agramonte-Hevia J, Barrera D, Jiménez-Orozco A, García-Mondragón MJ, Mendoza-Patiño N, Landa A, Mandoki J.” 4-Hydroxycoumarin disorganizes the actin cytoskeleton in B16–F10 melanoma cells but not in B82 fibroblasts, decreasing their adhesion to extracellular matrix proteins and motility”. Cancer Lett ,198; 179–186, 2003.
Sutton A, Friand V, Papy-Garcia D, Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O, Kraemer M, Saffar L, Perret GY, Courty J, Gattegno L, Charnaux N. “Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells”. Mol Cancer Ther, 6; 2948–2958, 2007.
Gerard C, Rollins BJ.” Chemokines and disease”. Nat Immunol ,2; 108–115, 2001.
Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poire, A, Saffar L, Kraemer M, VassyJ,Nahon P, Salzmann JL, et al.” Stromal cell-derived factor-1/chemokine (C-X-C motif) ligand 12 stimulates human hepatoma cell growth, migration, and invasion”. Mol Cancer Res, 5;21–33, 2007.
Kumar JA, Saidachary G, Mallesham G, Sridhar B, Jain N, Kalivendi SV, Jayathirtha Rao VJ, Raju BC.”Synthesis, anticancer activity and photophysical properties of novel substituted 2-oxo-2H-chromenylpyrazolecarboxylates”. European Journal of Medicinal Chemistry ,65;389-402, 2013.
Price LS, Leng J, Schwartz MA, Bokoch GM.” Activation of Rac and Cdc42 by Integrins Mediates Cell Spreading”. Mol Biol Cell ,9(7); 1863–1871, 1998.
Kajstura M, Halicka HD, Pryjma J, Darzynkiewicz Z.” Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete “sub-G1” peaks on DNA content histograms”. J Cytometry Part A ,71; 125–131, 2007.
Kumar JA, Saidachary G, Mallesham G, Sridhar B, Jain N, Kalivendi SV, Rao VJ, Raju BC.” Synthesis, anticancer activity and photophysical properties of novel substituted 2-oxo-2H-chromenylpyrazolecarboxylates.” Eur J Med Chem ,65; 389-402, 2013.
Colotta V, Cecchi L, Filacchioni G, Melani F, Palazzino G, Martini C, Giannaccini G, Lucacchini A.”Synthesis, binding studies, and structure activity relationships of 1-aryl- and 2-arylbenzopyranopyrazol-4-ones, central benzodiazepine receptor ligands”. J Med Chem ,31(1); 1–3, 1988.
Hlawaty H, Suffee N, Sutton A, Oudar O, Haddad O, Olivier V, Laguillier-Morizot C, Gattegno L, Letourneur D, Charnaux N.” Low molecular weight fucoidan prevents intimal hyperplasia in rat injured thoracic aorta through the modulation of matrix metalloproteinase-2 expression”. Biochem Pharmacol ,81(2); 233-43, 2011.
Abe K, Matsuki N.” Measurement of cellular 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT”. Neurosci Res ,38; 325-329, 2000.
Li R, Xie J, Wu H, Li G, Chen J, Chen Q, Wang L, Xu B.” Syndecan-4 shedding impairs macrovascular angiogenesis in diabetes mellitus”. Biochem Biophys Res Comm ,474; 15-21, 2016.
Haddad O, Guyot E, Marinval N, Chevalier F, L Maillard, Gadi L, Laguillier-Morizot C, Oudar O, Sutton A, Charnaux N, Hlawaty H.” Heparanase and syndecan-4 are involved in low molecular weight fucoidan-induced angiogenesis”. Mar Drugs 13; 6588–6608, 2015.
Sutton A, Friand V, Brule-Donneger S, Chaigneau T, Ziol M, Sainte-Catherine O, Poiré A, Saffar L, Kraemer M, Vassy J, Nahon P, Salzmann JL, Gattegno L, Charnaux N.” Stromal cell-derived factor-1/CXCL12 stimulates human hepatoma cell growth, migration and invasion”. Mol Cancer Res, 5 (1); 21–33, 2007.
Haddad O, Guyot E, Marinval N, Chevalier F, Maillard L, Gadi L, Laguillier-Morizot L, Oudar L, Sutton A, Charnaux N, Hlawaty H.”Heparanase and Syndecan-4 Are Involved in Low Molecular Weight Fucoidan-Induced Angiogenesis”. Mar Drugs ,13(11); 6588-6608, 2015.
Grover J, Kumar V, Sobhia ME, Jachak MS.” Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno [4, 3-c] pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors”. Bioorganic & Medicinal Chemistry Letters ,24;4638–4642, 2014.
Hamdi N, Fischmeister C, Puerta MC, Valerga P.” A rapid access to new coumarinylchalcone and substituted chromeno[4,3-c]pyrazol-4(1H)-ones and their antibacterial and DPPH radical scavenging activities”. Med Chem Res ,20;522-530, 2011.
Sun Z, Khan J, Makowska-Grzyska M, Zhang M, Cho JH, Suebsuwong C, Vo P, Gollapalli DR, Kim Y, Joachimiak A, Hedstrom L, Cuny GD.” Synthesis, in Vitro Evaluation and Cocrystal Structure of 4-Oxo-benzopyrano[4,3-c]pyrazole Cryptosporidium parvum Inosine 5′-Monophosphate Dehydrogenase (CpIMPDH) Inhibitors”. J Med Chem, 57;10544-10550, 2014.
Manmohan Reddy Leleti, William D. Thomas, Penglie Zhang, Andrew M.K. Pennell, Inventors, Chemocentryx, Inc. Filed March 30th 2007, and issued October 11th 2007. Cxcr4 modulators. Patent n° WO 2007115232 A2.
Krauth F , Dahse H-M, Rüttinger H-H, Frohberg P.” Synthesis and characterization of novel 1, 2, 4-triazine derivatives with antiproliferative activity”. Bioorganic and Medicinal Chemistry ,10; 1816-1821, 2010.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.